Similar articles

• Urinary leukotriene E4.

  Rabinovitch N. Rabinovitch N. Immunol Allergy Clin North Am. 2007 Nov;27(4):651-64; vii. doi: 10.1016/j.iac.2007.09.004. Immunol Allergy Clin North Am. 2007. PMID: 17996582 Review.
• Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease.

  Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, DeBaun MR. Field JJ, et al. Am J Hematol. 2009 Apr;84(4):231-3. doi: 10.1002/ajh.21370. Am J Hematol. 2009. PMID: 19291727
• Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha.

  Tanaka H, Saito T, Kurokawa K, Teramoto S, Miyazaki N, Kaneko S, Hashimoto M, Abe S. Tanaka H, et al. Allergy. 1999 May;54(5):489-94. doi: 10.1034/j.1398-9995.1999.00011.x. Allergy. 1999. PMID: 10380781 Clinical Trial.
• [The therapeutic potentials of antileukotriene preparations in bronchial asthma patients].

  Fedoseev GB, Emel'ianov AV, Krasnoshchekova OI. Fedoseev GB, et al. Ter Arkh. 1998;70(8):81-4. Ter Arkh. 1998. PMID: 9770758 Review. Russian. No abstract available.
• Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation.

  Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF. Green SA, et al. Thorax. 2004 Feb;59(2):100-4. doi: 10.1136/thorax.2003.006825. Thorax. 2004. PMID: 14760145 Free PMC article.